You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, April 2021
|
| DOI | 10.1186/s13195-021-00813-8 |
| Pubmed ID | |
| Authors |
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings |
X Demographics
The data shown below were collected from the profiles of 73 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 14% |
| Japan | 9 | 12% |
| United Kingdom | 6 | 8% |
| Canada | 3 | 4% |
| France | 3 | 4% |
| Germany | 2 | 3% |
| Spain | 2 | 3% |
| Sweden | 1 | 1% |
| Australia | 1 | 1% |
| Other | 0 | 0% |
| Unknown | 36 | 49% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 54 | 74% |
| Scientists | 11 | 15% |
| Practitioners (doctors, other healthcare professionals) | 7 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 531 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 531 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 45 | 8% |
| Researcher | 44 | 8% |
| Student > Bachelor | 40 | 8% |
| Other | 34 | 6% |
| Student > Master | 27 | 5% |
| Other | 57 | 11% |
| Unknown | 284 | 53% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 55 | 10% |
| Medicine and Dentistry | 46 | 9% |
| Biochemistry, Genetics and Molecular Biology | 33 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 25 | 5% |
| Agricultural and Biological Sciences | 15 | 3% |
| Other | 54 | 10% |
| Unknown | 303 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 990. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2023.
All research outputs
#16,700
of 25,743,152 outputs
Outputs from Alzheimer's Research & Therapy
#3
of 1,500 outputs
Outputs of similar age
#695
of 456,996 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 54 outputs
Altmetric has tracked 25,743,152 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,500 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 456,996 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.